Ceribell Reports Strong Q4 & FY2025 Revenue Growth, Multiple FDA Clearances, and Positive 2026 Outlook

summarizeSummary

Ceribell announced strong Q4 and full-year 2025 financial results, including 34% and 36% revenue growth respectively, alongside multiple FDA clearances and a Breakthrough Device Designation that significantly expand its addressable market. The company also provided positive revenue guidance for 2026.

check_boxKey Events

• Strong Revenue Growth Reported

  Ceribell reported total revenue of $24.8 million for Q4 2025, a 34% increase year-over-year, and $89.1 million for the full year 2025, a 36% increase over 2024. This growth was driven by expansion into new accounts and increased adoption within existing accounts.

• Significant Regulatory Milestones Achieved

  The company received FDA 510(k) clearance for a continuous monitoring solution for delirium and for its Clarity algorithm for neonates, making it the first and only FDA-cleared seizure detection algorithm for pre-term neonates through adults. Additionally, it secured FDA Breakthrough Device Designation for a first-in-class large vessel occlusion (LVO) stroke detection and monitoring solution, unlocking market opportunities exceeding $1.5 billion.

• Positive 2026 Revenue Guidance

  Ceribell expects full-year 2026 revenue to be in the range of $111 million to $115 million, representing approximately 25% to 29% growth over 2025.

• Cash Position Provides Runway

  The company ended 2025 with $159.3 million in cash, cash equivalents, and marketable securities, providing a solid financial foundation for continued operations and growth initiatives.

auto_awesomeAnalysis

This filing is highly important as Ceribell, a medical technology company, reported robust revenue growth for both the fourth quarter and full year 2025, alongside significant regulatory achievements. The multiple FDA clearances and a Breakthrough Device Designation for LVO stroke detection are pivotal, as they unlock substantial new market opportunities, which management estimates to exceed $1.5 billion. This strategic expansion, coupled with positive revenue guidance for 2026, indicates strong operational momentum and future growth potential, despite continued net losses common for high-growth companies in this sector. Investors should monitor the adoption rate of these newly cleared solutions and the company's progress towards profitability.